Featured
Boston Scientific's Stock Tumbles 30% Amid Product Woes and Recall Fallout
A 17.6% single-day crash and regulatory hurdles test investor faith. Can Boston Scientific's innovation and FDA wins turn the tide?
A 17.6% single-day crash and regulatory hurdles test investor faith. Can Boston Scientific's innovation and FDA wins turn the tide?